- Conditions
- Danon Disease
- Interventions
- RP-A501
- Biological
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 8 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 478
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- eplerenone, placebo
- Drug
- Lead sponsor
- Subha Raman
- Other
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis, Pectus Excavatum, Chronic Pain, Musculoskeletal Pain
- Interventions
- Not applicable- observational study
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 14 Years to 26 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- ASP2957, Methylprednisolone, Prednisolone, Sirolimus
- Genetic · Drug
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 36 Months · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SGT-003
- Genetic
- Lead sponsor
- Solid Biosciences Inc.
- Industry
- Eligibility
- 0 Years to 17 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Refractive Errors
- Interventions
- Acuity 200 (Fluoroxyfocon A) contact lens, Acuity 100 (Hexafocon A) contact lens
- Device
- Lead sponsor
- Acuity Polymers, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • Edina, Minnesota • Pittsford, New York
- Conditions
- Muscular Dystrophies, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy
- Interventions
- Retrograde high pressure transvenous perfusion with normal saline
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
- Interventions
- Vatiquinone, Placebo
- Drug · Other
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Up to 20 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Male only
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
- Conditions
- Myopathy, Neuropathy, Glycogen Storage Disease Type II (Late-onset Pompe Disease)
- Interventions
- Observational study
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SGT-003, Placebo
- Drug
- Lead sponsor
- Solid Biosciences Inc.
- Industry
- Eligibility
- 7 Years to 11 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Flower Mound, Texas • Norfolk, Virginia
- Conditions
- Nondystrophic Myotonias, Myotonia Congenita, Myotonic Disorders
- Interventions
- Not listed
- Lead sponsor
- Richard Barohn, MD
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Boston, Massachusetts • Rochester, New York + 1 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAV2.5-CMV-minidystrophin (d3990)
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 5 Years to 15 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Becker Muscular Dystrophy
- Interventions
- (+)-Epicatechin
- Drug
- Lead sponsor
- Epirium Bio Inc.
- Industry
- Eligibility
- 16 Years to 59 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Sacramento, California • St Louis, Missouri
- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- FSHD-specific functional rating scale, Electrical Impedance Myography
- Diagnostic Test · Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 5 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Eplerenone, Spironolactone
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more
- Conditions
- Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency), Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency), Limb-Girdle Muscular Dystrophy, Type 2I (FKRP-deficiency)
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Charlotte, North Carolina
- Conditions
- Oculopharyngeal Muscular Dystrophy
- Interventions
- BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-301: Dose escalation phase 1b cohort 3, BB-301: Dose expansion phase 2a
- Genetic
- Lead sponsor
- Benitec Biopharma, Inc.
- Industry
- Eligibility
- Up to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2040
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myotonic Dystrophy Type 1
- Interventions
- rhIGF-I/rhIGFBP-3, placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 12
- States / cities
- Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
- Conditions
- Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
- Interventions
- Placement of the BrainGate2 sensor(s) into the motor-related cortex
- Device
- Lead sponsor
- Leigh R. Hochberg, MD, PhD.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2038
- U.S. locations
- 6
- States / cities
- Sacramento, California • Stanford, California • Atlanta, Georgia + 3 more
- Conditions
- Muscular Dystrophy (DMD)
- Interventions
- RO7239361, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 10 Years · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Gainesville, Florida + 7 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sodium Nitrate, Sodium Nitrate - double dose, Placebo, Increased exercise intensity
- Dietary Supplement · Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 15 Years to 45 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California